Bortezomib (Velcade) treatment of AL amyloidosis: Indiana University experience

Research output: Contribution to journalArticle

2 Scopus citations

Abstract

Primary treatment of AL amyloidosis is to target the plasma cell clone which produces the immunoglobulin light chain precursor of amyloid fibrils. A number of chemotherapeutic regimens have been used and all have shown varying response in individual patients. Most recently, bortezomib (Velcade) has been used with consistent success as not only a primary but also a secondary line therapy for patients with either multiple-myeloma or AL amyloidosis. Here, we report the experience with use of bortezomib for AL amyloidosis at Indiana University Medical Center.

Original languageEnglish (US)
Number of pages1
JournalAmyloid
Volume18
Issue numberSUPPL. 1
DOIs
StatePublished - Jun 2011

ASJC Scopus subject areas

  • Internal Medicine

Fingerprint Dive into the research topics of 'Bortezomib (Velcade) treatment of AL amyloidosis: Indiana University experience'. Together they form a unique fingerprint.

  • Cite this